

HCPCS Quarterly Update

Effective for dates of service on or after April 1, 2019, HCPCS codes C9044 (injection, cemiplimab-rwlc, 1mg) and C9045 (Injection, moxetumomab pasudotox-tdfk, 0.01 mg) have been added as Medi-Cal benefits.

For complete details, please refer to the following links:

<http://files.medi-cal.ca.gov/pubsdoco/bulletins/artfull/gm201905.asp#a1>